News
Select year:
2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016
Click here for announcements regarding managers transactions.
Click here for news in Danish.
June 26, 2025 | Press Releases
Bavarian Nordic Announces the Initiation of Clinical Trials of Mpox Vaccine in Infants and Pregnant Women June 18, 2025 | Company Announcements
Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 MillionJune 12, 2025 | Press Releases
Bavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in ChildrenMay 09, 2025 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Three Months of 2025May 06, 2025 | Company Announcements
Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox VaccinesMay 02, 2025 | Press Releases
Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United KingdomApril 16, 2025 | Company Announcements
Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)April 09, 2025 | Company Announcements
Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/SMarch 31, 2025 | Company Announcements
Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine March 12, 2025 | Company Announcements
Bavarian Nordic A/S – Notice Convening Annual General Meeting March 07, 2025 | Press Releases
Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and OlderMarch 05, 2025 | Company Announcements
Bavarian Nordic Publishes Annual Report 2024February 28, 2025 | Company Announcements
Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and OlderFebruary 25, 2025 | Press Releases
Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine February 14, 2025 | Company Announcements
Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and OlderFebruary 03, 2025 | Company Announcements
Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025January 31, 2025 | Company Announcements
Bavarian Nordic – Completion of Share Buy-Back ProgramJanuary 31, 2025 | Company Announcements
Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and OlderJanuary 27, 2025 | Company Announcements
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program January 20, 2025 | Company Announcements
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program January 09, 2025 | Company Announcements
Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 MillionDecember 16, 2024 | Press Releases
Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India December 13, 2024 | Company Announcements
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic December 11, 2024 | Company Announcements
Bavarian Nordic to Launch DKK 150 Million Share Buy-back ProgramNovember 29, 2024 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise